Aktienanalyse zu Akari Therapeutics PLC (AKTX)AKTXAkari Therapeutics PLC

Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Akari Therapeutics PLC (AKTX) is not a good buy. The stock is trading at $7.37, significantly below its 52-week high of $29.32, indicating a substantial decline of 70.66% over the past year. The RSI is at 38.906, suggesting it is nearing oversold territory but not yet a strong buy signal. Furthermore, the forward P/E is 0, reflecting no earnings expected in the near term, which raises concerns about its profitability and financial health. The main risk is the negative net income, which reached -14,455,000 USD in Q1 2026, indicating ongoing financial struggles.

3 analysts cover AKTX: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 3.33.